ARID1A and cancer: Promising targets for potentially interesting inhibitors are the proteins of the JAK/STAT, Wnt/β-catenin, Hedgehog and Notch signalling pathways, inhibitors that target mutations in chromatin-remodelling genes, such as ARID1A, PBRM1, and BAP1, and inhibitors of cancer-associated fibroblasts [8].